智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的恩格列净二甲双胍缓释 片(II)《药品注册证书》。恩格列净二甲双胍缓释片(II)是恩格列净和盐酸二甲双胍的复方制剂，适用于 正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。 ...

Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate from the National Medical Products Administration for its drug, Ertugliflozin Metformin Extended-Release Tablets (II), indicating a significant advancement in its product portfolio for diabetes treatment [1] Group 1: Drug Approval Details - The drug is a combination formulation of Ertugliflozin and Metformin Hydrochloride, aimed at improving blood sugar control in adult patients with type 2 diabetes who are already receiving treatment with these medications [1] - The company received the acceptance notice for the drug's marketing authorization application in June 2024 and has recently obtained approval from the National Medical Products Administration [1] - The issuance of the drug registration certificate is considered equivalent to passing the consistency evaluation as per national policy regulations [1]